Between 1981 and 1985, 290 patients with malignant soft tissue tumors were registered in the CWS-81 study. These patients came from 48 clinics in West Germany, 185 of them (63.8%) were rhabdomyosareomas (RMS). The disease-free survival rate (DSF) for stage I is 83%, for stage II 64%, for stage III 52%, for stage IV 33% and for stages I-IV 57%. The median observation time is 27 months. The DSF rates by site of tumor are the following: .paratesticular RMS 89%, RMS of the orbit 80%, urogenital RMS 67%, RMS of the head and neck (orbit excluded) 49%, abdominal RMS 37%, RMS of the extremities 23%. We checked the prognostic significance of histologic subtypes (alveolar versus embryonal RMS), the influence of primary bone involvement, the influence of lymph node involvement, tumor diameter and the influence of tumor reduction per unit of time under initial cytostatic treatment. Tumor reduction per unit of time was the major hazard function affecting relapse-free survival time.
Response under initial chemotherapy up to week 7 was classed into 4 groups: tumor regression complete (100% DSF rate), regression >2/3 but not complete (67% DSF rate), regression <2/3-1/3 (25% DSF rat~ and tumor reduction <1/3 or tumor progression (27% DSF rate). This e very new and important aspect, valid for individual treatment strategy as well as for prognosis of therapeutic studies in the future.
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TREATMENT OF METASTATIC NEUROBLASTOMA WITH MEIAIODOBENZYL-GUANEDINE IN CHILDREN Th. Klingebiel,J.Treuner,D.Niethammer,U.Feine,W.MOllerSchauenburg,J.Meinke We treated 9 children withneuroblsstoma with Metaiodobenzylgusnedine (MIBG) in altogether 23 treatment courses. 4 of these had a relapse of neuroblastama, 3 had never reached a remission in spite of very intensive therapy and 2 were treated during the 1st or 2nd remission. 5 of these children lost their bone pain and fever during the first P days of therapy. In 6 of 7 children with a manifest tumor the solid tumor part as well as the bone marrow-infiltration responded to the MIBG-therapy:Response extended from transitory decrease of the tumor mass to complete disappearance of great abdominal tumors. We also saw a stabilization of osteolytic lesions, a decrease of elevated serum catecholamines and a decrease of bone marrow infiltration. 5 of the 7 children with a manifest tumor died of the tumor progression 55 to 249 days after the begin of MIBG-treatment. 2 lived 6ithout evidence of disease up to 35o days after begin of MIBG-treatment after having transplanted with autologous bone marrow. All the children tolerated the therapy very well. For them and their parents the procedure seemed to be much less harmful than chemotherapy. Side effects were only seen as transitory bone marrow depression. No changes in blood pressure or adrenal function were observed. Before using MIBG therapeutically ~e had demostrated,that it is a useful substance far scintigraphic imaging of neuroblastoma(J.Treuner et al, NucCompact 15,23,1984) and we had investigated the cytotoxieity and uptake in various neuroblastoma cell-lines(J.Buek et al,Cancer Rea.in press). MIBG is a new therapeutic substance which's effect in neuroblastoma relapse patients could be proved and which seems to be very promising in close connection to bone marrow transplantation as well as at a more early moment in neuroblastoma therapy. Among solid t~mours in childhood neuroblastoma stands out by frequent and early dissemination in the skeleton which may cause symptoms bef~ clinical manifestation of the primary tumour and require a roentgenological differentiation from other primary or secondary bone lesions in this age group, e.g. leukaemla, osteosarc~ Ewing's sarcoma, Hodgkin's disease, histiocytosis X, Wilms'tumour, rhabdomyosarcoma and osteomyelitis. In a review of the X-ray findings in 13 children (age range 1 to 12 years; median age 4.8 years) more than 40 skeletal lesions of neuroblastoma were analysed and compared with other skeletal lesions in this age grou~. Following patterns of skeletal involvement in neuroblastoma were revealed: (1) multifocal, rapidly progressive dissemination in the skeleton, (2) frequent localisation in the skull (9 of d3 pts.) in a combination of -multiple p~uctiform osteolytic areas, Diagnos~ik ~ud Kinderheilkumde, Klinikum der RWTH, D-5100 Aachen
